

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroTech Medical (Hangzhou) Co., Ltd.**

**微泰醫療器械(杭州)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2235)**

- (1) PROPOSED ELECTION OF DIRECTORS (OTHER THAN INDEPENDENT NON-EXECUTIVE DIRECTORS);**
- (2) PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS;**
- (3) PROPOSED APPOINTMENT OF MEMBERS OF THE BOARD COMMITTEES;**
- (4) PROPOSED ELECTION OF SUPERVISORS (OTHER THAN EMPLOYEE REPRESENTATIVE SUPERVISOR);**
- (5) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND**
- (6) CLOSURE OF REGISTER OF MEMBERS**

**I. PROPOSED ELECTION OF DIRECTORS (OTHER THAN INDEPENDENT NON-EXECUTIVE DIRECTORS) OF THE SECOND SESSION OF THE BOARD**

Given the expiry of the term of office of the Directors of the first session of the board (the “**Board**”) of directors (the “**Directors**”) of MicroTech Medical (Hangzhou) Co., Ltd. (the “**Company**”), the Board convened a meeting on the date of this announcement to propose the election of the Directors (other than independent non-executive Directors) of the second session of the Board.

The Board proposes to elect Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu as the executive Directors of the second session of the Board, and to elect Mr. Mao Shuo and Ms. Gao Yun as the non-executive Directors of the second session of the Board, and authorize the Board to fix their remuneration. Their biographical details are set out in Appendix I to this announcement.

The nomination committee of the Company (the “**Nomination Committee**”), having reviewed the composition of the Board and the Strategic Committee of the Board and assessed the backgrounds and experiences of Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui, Ms. Liu Xiu, Mr. Mao Shuo and Ms. Gao Yun, recommends that Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu be elected as the executive Directors of the Company, and Mr. Mao Shuo and Ms. Gao Yun be elected as the non-executive Directors of the Company at the forthcoming extraordinary general meeting of the Company (the “**EGM**”) in accordance with the nomination policy and board diversity policy of the Company (including but not limited to gender, age, cultural and educational background, ethnicity, geographical location, professional experience, skills, knowledge and length of service). In view of their extensive knowledge and invaluable experience, the Board accepts the nomination by the Nomination Committee and it considers that their election is in the best interests of the Company and all shareholders of the Company (the “**Shareholders**”).

Mr. Hu Xubo, a non-executive Director, has informed the Board that he will retire as a non-executive Director and will not seek re-election. Mr. Hu Xubo will cease to be a non-executive Director of the Company and a member of the Strategy Committee of the Board with effect from the date of election of the second session of the Board at the EGM. The Board would like to express its sincere gratitude to Mr. Hu Xubo for his past contributions to the Company. To the best of the Board’s knowledge and belief, having made all reasonable enquiries, Mr. Hu Xubo has confirmed to the Board that there is no disagreement between him and the Board and that he is not aware of any matter that needs to be brought to the attention of the Shareholders in relation to his retirement.

Saved as disclosed in this announcement, there are no matters in relation to proposed election of Directors (other than independent non-executive Directors) that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

## **II. PROPOSED ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF THE SECOND SESSION OF THE BOARD**

Given the expiry of the term of office of the Directors of the first session of the Board of the Company, the Board convened a meeting on the date of this announcement to propose the election of the independent non-executive Directors of the second session of the Board.

The Board proposes to elect Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua as the independent non-executive Directors of the second session of the Board, and authorize the Board to fix their remuneration.

The Nomination Committee, having reviewed the composition of the Board and the Strategy Committee of the Board and having assessed the backgrounds and experiences of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua, recommends that Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng, and Dr. Cheng Hua be elected as the independent non-executive Directors of the Company at the EGM in accordance with the nomination policy and board diversity policy of the Company (including but not limited to gender, age, cultural and educational background, ethnicity, geographical location, professional experience, skills, knowledge and length of service). Each of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua has extensive expertise and experience in accounting, smart healthcare and corporate management, and they have confirmed their independence pursuant to Rule 3.13 of the Listing Rules. The Nomination Committee has also assessed and was satisfied with their independence based on the independence criteria as set out in Rule 3.13 of the Listing Rules.

In view of the extensive knowledge and invaluable experience of Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua, the Board accepts the nomination proposed by the Nomination Committee. Dr. Li Lihua, Mr. Ho Kin Cheong Kelvin, Ms. Wang Chunfeng and Dr. Cheng Hua will bring a broader perspective to the Board and provide new notions for the Company's overall strategic planning and business development. The Board is of the view that their election is in the best interests of the Company and all Shareholders. Their biographical details are set out in Appendix I to this announcement.

Saved as disclosed in this announcement, there are no matters in relation to proposed election of independent non-executive Directors that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

### **III. PROPOSED APPOINTMENT OF MEMBERS OF THE COMMITTEES UNDER THE SECOND SESSION OF THE BOARD**

Given the expiry of the term of office of the Directors of the first session of the Board of the Company, the Board convened a meeting on the date of this announcement to propose the appointment of members of the committees under the second session of the Board, with effect from the date of the consideration and approval of the members of the second session of the Board (including independent non-executive Directors) at the EGM, details of which are set out below:

#### **Audit Committee:**

Mr. Ho Kin Cheong Kelvin (*Chairperson*)

Ms. Gao Yun

Ms. Wang Chunfeng

#### **Remuneration and Assessment Committee:**

Ms. Wang Chunfeng (*Chairperson*)

Dr. Shi Yonghui

Mr. Ho Kin Cheong Kelvin

#### **Nomination Committee:**

Dr. Li Lihua (*Chairperson*)

Dr. Zheng Pan

Dr. Cheng Hua

#### **Strategy Committee:**

Dr. Zheng Pan (*Chairperson*)

Dr. Li Lihua

Dr. Shi Yonghui

### **IV. PROPOSED ELECTION OF SUPERVISORS (OTHER THAN EMPLOYEE REPRESENTATIVE SUPERVISOR) OF THE SECOND SESSION OF THE SUPERVISORY COMMITTEE**

Given the expiry of the term of office of the supervisors (the “**Supervisor(s)**”) of the first session of the supervisory committee of the Company (the “**Supervisory Committee**”), the Supervisory Committee convened a meeting on the date of this announcement to propose the election of the Supervisors (other than employee representative Supervisor) of the second session of the Supervisory Committee.

The Supervisory Committee proposes to elect Mr. Lyu Cheng and Mr. Zhao Zhiheng as the shareholders’ representative Supervisors of the second session of the Supervisory Committee, and authorize the Board to fix their remuneration. Their biographical details are set out in Appendix II to this announcement.

Saved as disclosed in this announcement, there are no matters in relation to proposed election of Supervisors that need to be brought to the attention of the Shareholders and there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

## V. PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

On February 17, 2023, the State Council and the CSRC issued the “Decision of the State Council to Repeal Certain Administrative Regulations and Documents (《國務院關於廢止部分行政法規和文件的決定》)” and the “Trial Measures for the Administration of Overseas Securities Offering and Listing by Domestic Enterprises (《境內企業境外發行證券和上市管理試行辦法》)” (collectively, the “**New PRC Regulations**”), respectively, with effect from March 31, 2023. At the same time, the “Mandatory Provisions for the Articles of Association of Companies Listed Overseas (Zheng Wei Fa [1994] No. 21) (《到境外上市公司章程必備條款》(證委發[1994]21號文))” issued by the Securities Commission of the State Council and the National Economic System Reform Commission on August 27, 1994 (the “**Mandatory Provisions**”) and the Special Regulations of the State Council on Overseas Offering and Listing of Shares by Joint Stock Limited Companies (《國務院關於股份有限公司境外募集股份及上市的特別規定》) issued by the State Council on August 4, 1994 were repealed on the same date as the New PRC Regulations took effect. PRC issuers shall make reference to the Guidelines on Articles of Association of Listed Companies (2022 Revision) \*(《上市公司章程指引(2022年修訂)》)(the “**PRC Guidelines on AoA**”) issued by the CSRC in formulating their articles of association, and the Mandatory Provisions are no longer applicable. Pursuant to the New PRC Regulations, the Hong Kong Stock Exchange has made consequential amendments to the Listing Rules with effect from August 1, 2023.

Given the above, the Board proposes to make amendments (the “**Proposed Amendments to the Articles of Association**”) to the existing articles of association of the Company (the “**Articles of Association**”) in order to remove provisions that are obsolete as a result of the repeal of the Special Regulations and the Mandatory Provisions, to reflect the New PRC Regulations, to embody certain requirements of the PRC Guidelines on AoA and to comply with the requirements of the Listing Rules. Details of the Proposed Amendments to the Articles of Association will be set out in the circular in relation to the EGM to be dispatched to the Shareholders.

The Proposed Amendments to the Articles of Association will not undermine the protection of the Shareholders and will not have material impact on measures to protect the Shareholders. In particular, according to the New PRC Regulations, domestic shares and H shares shall be regarded as the same class of ordinary shares, and holders of domestic shares and H shares shall no longer be regarded as different classes of shareholders, the substantive rights attached to the two types of shares (including voting rights, dividends and asset distribution in case of liquidation) shall be identical. Therefore, the removal of the class meeting requirements from the Articles of Association will not undermine the protection of the Shareholders. In addition, given that there are sufficient channels to resolve disputes (such as court proceedings in Mainland China and Hong Kong) to enable the Shareholders to exercise their rights under the Articles of Association, the removal of the arbitration provision from the Articles of Association and the abolition of arbitration as the sole means of dispute resolution will not affect the protection of the Shareholders.

The amended Articles of Association will become effective from the date of the EGM, at which the relevant resolution will be considered and, if thought fit, approved by the Shareholders. Prior to that, the existing Articles of Association shall remain effective.

Upon the Proposed Amendments to the Articles of Association taking effect, the Company will continue to comply with Appendix 3 to the Listing Rules to meet the core shareholder protection standards by means of compliance with PRC laws in combination with its Articles of Association and will further monitor its ongoing compliance with these rules.

## **VI. GENERAL**

The Company will convene the EGM, class meeting of holders of H shares of the Company (the “**H Shares**”), and class meeting of holders of unlisted shares of the Company on December 27, 2023, for the relevant Shareholders to consider and, if thought fit, to approve, among other things, (i) the proposed election of Directors of the second session of the Board, (ii) the proposed election of Supervisors of the second session of the Supervisory Committee, and (iii) the Proposed Amendments to the Articles of Association. A circular containing, among other things, further details of the aforesaid matters, together with the notice of EGM and class meetings will be despatched to the Shareholders as soon as practicable in accordance with the requirements under the Listing Rules and the Articles of Association currently in force.

## **VII. CLOSURE OF REGISTER OF MEMBERS**

The register of members of H Shares has been scheduled to close from Wednesday, December 20, 2023 to Wednesday, December 27, 2023, both days inclusive, during which period no transfer of H Shares will be registered, in order to determine the holders of the H Shares who are entitled to attend and vote at the forthcoming EGM and the class meeting of holders of H Shares. To be eligible to attend and vote at the EGM and the class meeting of holders of H Shares, all transfer documents must be lodged with the Company’s H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Tuesday, December 19, 2023 for registration.

By order of the Board  
**MicroTech Medical (Hangzhou) Co., Ltd.**  
**Zheng Pan**  
*Chairman of the Board*

Hangzhou, the PRC, December 6, 2023

*As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Hu Xubo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.*



## APPENDIX I

Biographical details of Director candidates for the second session of the Board are set out below:

### I. EXECUTIVE DIRECTORS

**Dr. Zheng Pan (鄭攀)**, aged 52, is the chairman of our Board, an executive Director and the Chief Executive Officer of our Company. Dr. Zheng founded our Company in January 2011 and has been the chairman of the Board since March 2016 and the Chief Executive Officer of our Company since January 2011, respectively. He was re-designated as an executive Director of our Company in April 2021. He is primarily responsible for the overall strategic planning, business direction and operational management of our Company.

Dr. Zheng has nearly 20 years of experience in the healthcare industry. Prior to founding our Company, he successively served as a research assistant and a postdoc in Florida State University from 1999 to September 2004 in the United States. From October 2004 to July 2010, Dr. Zheng successively served as a senior mechanical engineer at Centurion Wireless Technologies and a manager at Flextronics San Jose Medical Products Center (美國偉創力聖荷西醫療產品中心), a medical solution provider company.

Dr. Zheng obtained the qualification of professorate senior engineer (教授級高級工程師) from Zhejiang Provincial Department of Human Resources and Social Security (浙江省人力資源和社會保障廳) in July 2012. Dr. Zheng was selected into the first batch of “521” Talents for Global Talents Introduction(杭州市第一批全球引才“521”人才) by Municipal Party Committee Organization Department (Talent Office) (杭州市委人才工作領導小組辦公室) in August 2011, and he won the Innovation Achievement Award of Overseas Returnee Contributions Awards (中國僑界貢獻獎(創新成果)) from All-China Federation of Returned Overseas Chinese in September 2014.

Dr. Zheng received a bachelor’s degree from Zhejiang Institute of Technology (浙江工學院) in the PRC with a major in Machine Design and Production Engineering in July 1993, a master’s degree from Zhejiang University (浙江大學) in the PRC with a major in Mechanics in March 1996 and a Ph.D. degree with a major in Mechanical Engineering from Florida State University in the United States in August 2004.

As at the date of this announcement, Dr. Zheng is deemed to be interested in the 41,690,719 H Shares (representing 23.98% of the total H share capital of the Company) and 82,009,537 domestic Shares (representing 39.39% of the total domestic share capital of the Company).

Dr. Zheng will not receive any remuneration for his appointment as an executive Director from the Company.

**Dr. Yu Fei (于非)**, aged 41, is an executive Director and the director of R&D Department of our Company. Dr. Yu joined our Group in July 2016 and was re-designated as our executive Director in April 2021. He is primarily responsible for the formulation of product development plans and management of R&D matters in respect of technology, project management and intellectual properties.

Prior to joining our Group, Dr. Yu served as a senior biomedical engineer in the Diabetes Division of Medtronic PLC. (美國美敦力公司), a medical technology company, from May 2013 to July 2016, where he was responsible for researching, developing, deploying and validating new electrochemical biosensor system. He has been serving as the R&D director and a Director of our Company since August 2016 and October 2020, respectively.

Dr. Yu received a bachelor's degree in Bioengineering from National University of Singapore in Singapore on June 30, 2007 and a Ph.D. degree in biomedical engineering from University of Southern California in the United States in May 2013. Dr. Yu was recognized as an overseas high-level talent in Zhejiang Province in April 2020.

Dr. Yu will not receive any remuneration for his appointment as an executive Director from the Company.

**Dr. Shi Yonghui (施永輝)**, aged 43, is an executive Director, the chief strategy & development officer and the senior vice president, and the secretary to the Board of our Group. Mr. Shi joined our Group in May 2021 and was appointed as our executive Director in June 2021. He was appointed as the secretary to the Board in August 2022. He is primarily responsible for the strategy, new business and corporate development matters of the Group and is also responsible for information disclosure and organizing Board and Shareholders' meetings.

Prior to joining our Group, Dr. Shi successively served as the research scientist from July 2007 to October 2008 and New Business Development Manager from November 2008 to June 2011 at Procter & Gamble Technology (Beijing) Co., Ltd. (北京寶潔技術有限公司), where he was responsible for various R&D and business development initiatives. From July 2013 to May 2021, he successively served as the senior manager and the senior director of Medtronic (Shanghai) Management Co., Ltd. (美敦力(上海)管理有限公司), head of corporate development, venture capital and innovation incubation department of Medtronic Greater China, and member of Medtronic Greater China Management Board, during which time he also served as an investment committee member of Medtronic China Venture Capital Fund, which focuses on the investment in high-growth startups with innovative medical technologies or service models, the chairman and general manager of Suzhou Meizhong Venture Capital Management Co., Ltd. (蘇州美眾創業投資管理有限公司), the director of Suzhou Medtronic Sequoia Venture Capital Management Co., Ltd. (蘇州美敦力紅杉創業投資管理有限公司), and the general manager of Shanghai Meiji Entrepreneurship Incubator Management Co., Ltd (上海美濟創業孵化器管理有限公司). Dr. Shi has been serving as the independent director of Scivita Medical Technology Co., Ltd(新光維醫療科技(蘇州)控股有限公司) since November 2022. He has been serving as an executive Director and the chief strategy & development officer of our Company since June and May 2021,



respectively. Since August 2022, Dr. Shi has been serving as an executive Director, the chief strategy & development officer and the senior vice president, and the secretary to the Board of the Company.

Dr. Shi received a bachelor's degree with a major in biochemistry and molecular biology and a Ph.D. degree with a major in biochemistry and molecular biology from Peking University in the PRC in July 2002 and July 2007, respectively. He also obtained a master's degree in business administration (in finance and healthcare management) from the Wharton School of the University of Pennsylvania in the United States in 2013. Dr. Shi was the co-recipient of the first prize of Natural Science of the Ministry of Education (教育部自然科學一等獎) granted by Ministry of Education, PRC in 2009, and he was also recognized as the co-recipient of the second prize of National Natural Science (國家自然科學二等獎) granted by the State Council, PRC in 2011.

As at the date of this announcement, Dr. Shi is deemed to be interested in the 590,900 H Shares (representing 0.34% of the total H share capital of the Company).

Dr. Shi will not receive any remuneration for his appointment as an executive Director from the Company.

**Ms. Liu Xiu (劉秀)**, aged 43, is an executive Director and the financial controller of our Group. Ms. Liu joined our Group in August 2020 and was re-designated as our executive Director in April 2021. She is primarily responsible for the financial matters management of the Company.

Prior to joining our Group, Ms. Liu served in multiple companies and has over 20 years of experience in financial and investment areas. From July 2003 to September 2012, Ms. Liu served various positions in Pan-China Certified Public Accountants LLP (天健會計師事務所), including, among others, senior project manager and manager. She then served as the financial director in Zhejiang Dajing Investment Co., Ltd. (浙江大晶投資有限公司), formerly known as Zhejiang University Venture Capital Co., Ltd. (浙江大學創業投資有限公司) from September 2012 to June 2017. During June 2017 to April 2020, she served successively as the risk control director of Investment Department of Wanma United Holding Group Co., Ltd. (浙江萬馬智能科技集團有限公司) and the partner of Hangzhou Silicon Valley True Stone Asset Management Co., Ltd. (杭州矽谷真石資產管理有限公司). Ms. Liu has been serving as an independent director of Ningbo Jiangfeng Electronic Materials Co., Ltd. (寧波江豐電子材料股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300666), since December 2020. She has been serving as the financial controller, the secretary to the Board and a director of our Company since August 2020 and October 2020, respectively. Since August 2022, Ms. Liu has been serving as an executive Director and the financial controller of the Company.

Ms. Liu received a bachelor's degree in economics from Central China Normal University (華中師範大學) in the PRC in June 2003 and a graduation certificate in Economics from Zhejiang University (浙江大學) in the PRC in October 2012. She was qualified as a certified public accountant in April 2003 by Ministry of Finance of the People's Republic of China, an internal auditor in November 2004 by Institute of

Internal Auditors, the senior accountant in April 2015 by Zhejiang Provincial Department of Human Resources and Social Security with authorization from the Provincial Senior Accountant Qualification Review Committee.

Ms. Liu will not receive any remuneration for her appointment as an executive Director from the Company.

## II. NON-EXECUTIVE DIRECTORS

**Mr. Mao Shuo (毛碩)**, aged 35, worked as a strategic consultant in the healthcare industry from January 2013 to November 2015 at IQVIA (艾昆緯), a healthcare company. He joined Qiming Venture Partners, a company engaging in venture capital investments, in November 2015 and served as an investment manager, vice president of investment and executive director.

Mr. Mao received a bachelor's degree in biomedical engineering from Tsing Hua University in June 2009, and a master's degree in technology entrepreneurship and management and a master's degree in electrical engineering in December 2011 from the University of Rochester.

Mr. Mao will not receive any remuneration for his appointment as a non-executive Director from the Company.

**Ms. Gao Yun (高韻)**, aged 36, has been a Director of our Company since May 2020. Ms. Gao joined our Group in May 2020 and was re-designated as our non-executive Director in April 2021. She is primarily responsible for overseeing Board affairs and giving strategic advice and guidance on the business operation of the Group.

Between August 2011 and January 2014, Ms. Gao served successively as an analyst and then senior analyst in IMS Health. In February 2014, she joined the Medtronic PLC. (美國美敦力公司), a medical technology company, as the specialist in the Strategy and Business Development Department for a certain period of time. After that, Ms. Gao also worked at SBCVC (HK) Ltd. (軟銀中國資本有限公司) as the investment manager. She has been successively serving as the investment manager, the senior investment manager, the vice president and executive director at Lilly Asia Ventures (禮來亞洲基金), an investment fund since October 2018.

Ms. Gao received a bachelor's degree in medicine from Fudan University in the PRC in June 2011 and a master's degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in December 2016.

Ms. Gao will not receive any remuneration for her appointment as a non-executive Director from the Company.

### III. INDEPENDENT NON-EXECUTIVE DIRECTORS

**Dr. Li Lihua (厲力華)**, aged 58, was appointed as an independent Director of the Company in October 2020 and transferred as an independent non-executive Director in April 2021. His main responsibility is to participate in the decision making of major events of the Company and to provide advice on corporate governance, audit and remuneration and evaluation of Directors, Supervisors and senior management.

Dr. Li served as an assistant professor and associate professor at the University of South Florida School of Medicine from 1994 to 2006. Since June 2006, He has served as the director of The Institute of Biomedical Engineering and Instrument, the Dean of the School of Life Information and Instrument Engineering, and the Dean of the Institute of Intelligent Health of Hangzhou Dianzi University (杭州電子科技大學).

Dr. Li is well-known in the field of science. In December 2006, he was selected as the first level of “The New Century 151 Talent Project” (新世紀151人才工程) of Zhejiang Province. In August 2006, he was appointed as “Qianjiang Scholar” Distinguished Professor of Zhejiang Higher Education Institution (浙江省高等學校“錢江學者”特聘教授). In September 2007, he was awarded the National Science Fund for Outstanding Young Scholars by the National Natural Science Foundation of China (國家自然科學基金委員會). In 2009, he was selected as the national talent of “New Century Millions of Talents Project”. Dr. Li is currently a member of the Science and Technology Development Advisory Committee of Zhejiang Province (浙江省科技發展諮詢委員會委員), a member of the Academic Advisory Committee of Zhijiang Laboratory(之江實驗室學術諮詢委員會), chairman of the Image Information and Control Professional Committee of the Chinese Society of Biomedical Engineering (中國生物醫學工程學會圖像信息與控制專業委員會), and vice chairman of the Medical Imaging Professional Committee of the Chinese Society of Image and Graphics (中國圖象圖形學會醫學影像專業委員會). Dr. Li plays a leading role in several programs, such as the Key Program under the National Natural Science Foundation of China, the Key Program of Joint Fund for Regional Innovation under the National Natural Science Foundation of China, and the Special Program for Strategic Science and Technology Innovation cooperation under China’s National Key R&D Programs.

Dr. Li received his ph. D. degree in Signal and Information Processing from Southeast University (東南大學) in China in November 1990.

Dr. Li will receive RMB100,000 per annum as allowance for his service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

**Mr. Ho Kin Cheong Kelvin (何建昌)**, aged 56, was appointed as an independent non-executive Director on April 21, 2021. He is primarily responsible for participating in the decision making for our Company’s significant events and advising on issues relating to corporate governance, audit and the remuneration and assessment of our Directors, Supervisors and senior management.

Mr. Ho has over 20 years of experience in finance and accounting, company secretary, initial public offering and debt restructuring areas. Mr. Ho worked at Grand Orient Holdings Limited (偉東集團有限公司) (stock code: 0106.HK) from June 1999 to October 2000, serving as the company secretary and chief financial officer. From December 2000 to November 2003, he worked for Hanny Magnetics Limited, a subsidiary of Hanny Holdings Limited (錦興集團有限公司) (currently known as Master Glory Group Limited) (stock code: 0275.HK) at which his last position was financial analyst. From January 2004 to September 2005, he worked for Friedmann Pacific Greater China Investments Limited (富泰大中華投資有限公司) (stock code: 1226.HK) as the company secretary and chief financial officer. From August 2006 to August 2008, he worked for Anhui Tianda Oil Pipes Company Limited (安徽天大石油管材有限公司) (stock code: 0839.HK) as company secretary and chief financial officer. From August 2008 to January 2010, he worked for FU JI Food and Catering Services Holdings Limited (福記食品服務控股有限公司) (currently known as Fresh Express Delivery Holdings Group Co., Limited) (stock code: 1175.HK) as company secretary and chief financial officer. From April 2010 to March 2012 and from May 2012 to December 2014, he worked for Greens Holdings Limited (格菱控股有限公司) (stock code: 1318.HK) at which his last position was company secretary and chief financial officer. From January 2016 to December 2017, he worked for Sand River Golf Club Limited (沙河高爾夫球會有限公司) as the company secretary and chief financial officer. From March 2019 to May 2020, he worked for Richly Field China Development Limited (裕田中國發展有限公司) (stock code: 0313.HK) as the company secretary and chief financial officer. From August 2020 to January 2022, Mr. Ho has been the company secretary and chief financial officer of China Wood International Holding Co., Limited (中木國際控股有限公司) (stock code: 1822.HK).

Mr. Ho was an independent non-executive director of Cheung Tai Hong Holdings Limited (currently known as ITC Properties Group Limited) (祥泰行集團有限公司) (stock code: 0199.HK) from October 2001 to May 2003 and a non-executive director of HongDa Financial Holding Limited (currently known as China Wood International Holding Co., Limited) (stock code: 1822.HK) (弘達金融控股有限公司) from April 2016 to April 2017. From August 2018 to February 2022, Mr. Ho has been an independent non-executive director of CECEP COSTIN New Materials Group Limited (In Provisional Liquidation) (中國節能海東青新材料集團有限公司) (“**CECEP COSTIN**”) (stock code: 2228.HK). Based on published information, CECEP COSTIN received a winding up petition and a summons for the appointment of joint provisional liquidators dated October 2017. Mr. Ho’s appointment was made subsequent to the winding up petition against CECEP COSTIN and he was appointed by the joint provisional liquidators to meet the relevant requirements under the Listing Rules. In February 2022, the listing status of CECEP COSTIN was cancelled by the Hong Kong Stock Exchange. From July 2020 to November 2022, Mr. Ho was an independent non-executive director of Rosan Resources Holdings Limited (融信資源控股有限公司) (stock code: 0578.HK). Since August 2020, he has been an independent non-executive director of Green Leader Holdings Group Limited (綠領控股集團有限公司) (stock code: 0061.HK). Since October 2020, he has been an independent non-executive director of Yadong Group Holdings Limited (亞東集團控股有限公司) (stock code: 1795.HK) and JW (Cayman) Therapeutics Co. Ltd (藥明巨諾(開曼)有限公司) (stock code: 2126.HK). Notwithstanding the above appointments as independent non-executive director, Mr. Ho confirmed that he will devote sufficient time to act as an independent non-executive

Director of our Company. In addition, Mr. Ho acting as independent non-executive director is neither a full-time member of the above-mentioned listed companies nor involved in day-to-day operations or management of the above-mentioned listed companies, and as such he has no executive or management responsibility.

Mr. Ho was admitted as an associate member of the Hong Kong Society of Accountants (currently known as The Hong Kong Institute of Certified Public Accountants) in June 1997 and a fellow member of The Association of Chartered Certified Accountants in the United Kingdom in April 2002. He has passed the Securities Broker Examination of The Stock Exchange of Hong Kong Limited in March 2000.

Mr. Ho obtained a bachelor degree of business administration from Hong Kong Baptist College (currently known as Hong Kong Baptist University) in Hong Kong in November 1990.

Mr. Ho will receive HK\$220,000 per annum as allowance for his service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

**Ms. Wang Chunfeng (王春鳳)**, aged 41, was appointed as an independent Director of our Company in October 2020 and re-designated as an independent non-executive Director in April 2021. She is primarily responsible for participating in the decision making for our Company's significant events and advising on issues relating to corporate governance, audit and the remuneration and assessment of our Directors, Supervisors and senior management.

Ms. Wang served successively as the supervisor, securities affairs representative and the director of the administrative management center of Enjoyor Co., Ltd. (銀江股份有限公司), whose shares are listed on the Shenzhen Stock Exchange (stock code: 300020) from September 2007 to July 2010. Since 2010, she has been working at Yinjiang Incubator Co., Ltd. (銀江孵化器股份有限公司) and she previously served as the chief executive officer and currently holds the position of vice chairperson.

Ms. Wang received a master's degree in business administration from Lanzhou University of Technology (蘭州理工大學) in the PRC in December 2015. She was granted the third prize of Hangzhou Science and Technology Progress Award (杭州市科技進步三等獎) by Hangzhou Science and Technology Bureau (杭州市科學技術局) in October 2011.

Ms. Wang will receive RMB100,000 per annum as allowance for her service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to her qualifications, experience, duties and responsibilities, and the prevailing market conditions.



**Dr. Cheng Hua (程華)**, aged 58, was appointed as an independent non-executive Director of our Company in December 2022. His main responsibility is to participate in the decision making of major events of the Company and to provide advice on corporate governance, audit and remuneration and evaluation of Directors, Supervisors and senior management.

Dr. Cheng acted as the deputy director of Institute of Science and Technology, Zhejiang Sci-Tech University from November 2005 to November 2016, the director of School of Economics and Management, Zhejiang Sci-Tech University from December 2016 to December 2020, and an instructor of Department of Business Management, Zhejiang Sci-Tech University from December 2020. Since December 2020, Dr. Cheng has been working as an independent director of Zhejiang Xingxing Refrigeration Co., Ltd.

Dr. Cheng was awarded a bachelor's degree in management engineering in July 1986 by Donghua University (formerly known as China Textile University), a master's degree in business management in March 1992 by Shanghai University of Finance and Economics, and a doctoral degree in agricultural economics and management in March 2004 by School of Management, Zhejiang University.

Dr. Cheng will receive RMB100,000 per annum as allowance for his service as an independent non-executive Director, which was determined by the Board based on the recommendation by the Remuneration and Assessment Committee of the Company with reference to his qualifications, experience, duties and responsibilities, and the prevailing market conditions.

If the above-mentioned candidates are appointed as Directors, they will each enter into a service contract with the Company and serve until the expiration of the second session of the Board.

Saved as disclosed above, as at the date of this announcement, each Director proposed to be elected (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, or other major appointments and professional qualifications; (ii) was not related to any Directors, Supervisors, senior management or substantial Shareholders of the Company; (iii) was not interested in any Shares within the meaning of Part XV of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong); and (iv) did not hold any other position with the Company or other members of the Group.



## APPENDIX II

Biographical details of candidates as Supervisors (other than employee representative Supervisor) for the second session of the Supervisory Committee are set out below:

**Mr. Lyu Cheng (呂承)**, aged 35, is a shareholders' representative Supervisor. Mr. Lyu joined our Group in October 2020 as a Supervisor. He is primarily responsible for supervising the performance of our Directors and members of senior management and performing other supervisory duties as a Supervisor.

Mr. Lyu has been successively serving as the investment manager and investment director of LYZZ Capital (上海禮澤投資管理有限公司), an investment company, since February 2017, where he was responsible for investment matters.

Mr. Lyu received a bachelor's degree in business administration from Glion Institute of Higher Education in Switzerland in May 2012 and a master's degree in tourism administration from George Washington University in the United States in May 2015.

Mr. Lyu will not receive any remuneration for his appointment as a Supervisor from the Company.

**Mr. Zhao Zhiheng (趙志恆)**, aged 40, is a shareholders' representative Supervisor. Mr. Zhao joined our Group in August 2013 as the manager of purchasing department. He is primarily responsible for supervising the performance of our Directors and members of senior management and performing other supervisory duties as a Supervisor.

Prior to joining our Group, he was the sole proprietor of Hangzhou Shangcheng District Xiuyushanju Handicraft Shop (杭州市上城區秀玉山居工藝品店) from January 2010 to December 2012. Mr. Zhao served as the purchasing manager of the Company from August 2013 to October 2020. Since October 2020, he has been serving as a Supervisor and the purchasing manager of the Company. Mr. Zhao has been serving as the Supervisor of Hangzhou Jienuotong Technology Materials Co., Ltd. (杭州捷諾通科技材料有限公司) (a wholly-owned subsidiary of the Company) since November 2021. Since February 2023, he has been serving as the Supervisor of Hangzhou MicroTech Medical Electronics Co., Ltd. (杭州微泰醫療電子有限公司) (a wholly-owned subsidiary of the Company).

Mr. Zhao graduated from Zhejiang University City College (浙江大學城市學院) in the PRC with a major in financial analysis in February 2007. He obtained his bachelor's degree in logistics management from Huazhong University of Science and Technology (華中科技大學) in the PRC in July 2019.

Mr. Zhao will not receive any remuneration for his appointment as a Supervisor from the Company.

If the above-mentioned candidates are appointed as Supervisors, they will each enter into a service contract with the Company and serve until the expiration of the second session of the Supervisory Committee.

Saved as disclosed above, as at the date of this announcement, each Supervisor proposed to be elected (i) did not hold any other directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, or other major appointments and professional qualifications; (ii) was not related to any Directors, Supervisors, senior management or substantial Shareholders of the Company; (iii) was not interested in any Shares within the meaning of Part XV of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong); and (iv) did not hold any other position with the Company or other members of the Group.